Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

PD-1 Restrains Radiotherapy-Induced Abscopal Effect.

Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED.

Cancer Immunol Res. 2015 Jun;3(6):610-9. doi: 10.1158/2326-6066.CIR-14-0138. Epub 2015 Feb 19.

2.

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.

Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED.

J Thorac Oncol. 2014 Jul;9(7):1036-40. doi: 10.1097/JTO.0000000000000177.

3.

B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation.

Gibbons RM, Liu X, Harrington SM, Krco CJ, Kwon ED, Dong H.

Cancer Immunol Immunother. 2014 Aug;63(8):859-67. doi: 10.1007/s00262-014-1563-6. Epub 2014 Jun 4.

4.

Endogenous tumor-reactive CD8+ T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth.

Liu X, Gibbons RM, Harrington SM, Krco CJ, Markovic SN, Kwon ED, Dong H.

Oncoimmunology. 2013 Jun 1;2(6):e23972. Epub 2013 Jun 6.

5.

B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim.

Gibbons RM, Liu X, Pulko V, Harrington SM, Krco CJ, Kwon ED, Dong H.

Oncoimmunology. 2012 Oct 1;1(7):1061-1073.

6.

Soluble B7-H1: differences in production between dendritic cells and T cells.

Frigola X, Inman BA, Krco CJ, Liu X, Harrington SM, Bulur PA, Dietz AB, Dong H, Kwon ED.

Immunol Lett. 2012 Feb 29;142(1-2):78-82. doi: 10.1016/j.imlet.2011.11.001. Epub 2011 Nov 25.

7.

B7-h1 expressed by activated CD8 T cells is essential for their survival.

Pulko V, Harris KJ, Liu X, Gibbons RM, Harrington SM, Krco CJ, Kwon ED, Dong H.

J Immunol. 2011 Dec 1;187(11):5606-14. doi: 10.4049/jimmunol.1003976. Epub 2011 Oct 24.

8.

MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells.

Erskine CL, Krco CJ, Hedin KE, Borson ND, Kalli KR, Behrens MD, Heman-Ackah SM, von Hofe E, Wettstein PJ, Mohamadzadeh M, Knutson KL.

J Immunol. 2011 Jul 1;187(1):316-24. doi: 10.4049/jimmunol.1100658. Epub 2011 May 25.

9.

Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.

Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED.

Clin Cancer Res. 2011 Apr 1;17(7):1915-23. doi: 10.1158/1078-0432.CCR-10-0250. Epub 2011 Feb 25.

10.

Tissue microarrays: one size does not fit all.

Eckel-Passow JE, Lohse CM, Sheinin Y, Crispen PL, Krco CJ, Kwon ED.

Diagn Pathol. 2010 Jul 7;5:48. doi: 10.1186/1746-1596-5-48.

11.

A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.

Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL.

Clin Cancer Res. 2010 Feb 1;16(3):825-34. doi: 10.1158/1078-0432.CCR-09-2781. Epub 2010 Jan 26.

12.

TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination.

Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, Dong H.

J Immunol. 2009 Sep 15;183(6):3634-41. doi: 10.4049/jimmunol.0900974. Epub 2009 Aug 26.

13.

Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.

Karyampudi L, Krco CJ, Kalli KR, Erskine CL, Hartmann LC, Goodman K, Ingle JN, Maurer MJ, Nassar A, Yu C, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL.

Cancer Immunol Immunother. 2010 Jan;59(1):161-71. doi: 10.1007/s00262-009-0738-z. Epub 2009 Jul 21.

14.

An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.

Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, Johnson EM, Erskine CL, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL.

Cancer Res. 2008 Jun 15;68(12):4893-901. doi: 10.1158/0008-5472.CAN-07-6726.

15.

The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity.

Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempski J, Gad EA, Disis ML, Knutson KL.

Blood. 2008 Feb 1;111(3):1472-9. Epub 2007 Nov 20.

16.

Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.

Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED.

Clin Cancer Res. 2007 Apr 1;13(7):2075-81.

17.

B cells are important as antigen presenting cells for induction of MHC-restricted arthritis in transgenic mice.

Taneja V, Krco CJ, Behrens MD, Luthra HS, Griffiths MM, David CS.

Mol Immunol. 2007 Apr;44(11):2988-96. Epub 2007 Feb 14.

18.

T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.

Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR.

J Clin Oncol. 2006 Sep 10;24(26):4254-61. Epub 2006 Aug 14.

PMID:
16908932
19.
20.

Expression and function of HLA-DR3 and DQ8 in transgenic mice lacking functional H2-M.

Rajagopalan G, Smart MK, Cheng S, Krco CJ, Johnson KL, David CS.

Tissue Antigens. 2003 Aug;62(2):149-61.

PMID:
12889995
21.

Expression and function of transgenic HLA-DQ molecules and lymphocyte development in mice lacking invariant chain.

Rajagopalan G, Smart MK, Krco CJ, David CS.

J Immunol. 2002 Aug 15;169(4):1774-83.

22.
23.

Identification of T cell determinants on human type II collagen recognized by HLA-DQ8 and HLA-DQ6 transgenic mice.

Krco CJ, Watanabe S, Harders J, Griffths MM, Luthra H, David CS.

J Immunol. 1999 Aug 1;163(3):1661-5.

24.

Short ragweed allergen induces eosinophilic lung disease in HLA-DQ transgenic mice.

Chapoval SP, Nabozny GH, Marietta EV, Raymond EL, Krco CJ, Andrews AG, David CS.

J Clin Invest. 1999 Jun;103(12):1707-17.

25.
27.

Human leukocyte antigen-DRB1*1502 (DR2Dw12) transgene reduces incidence and severity of arthritis in mice.

Gonzalez-Gay MA, Zanelli E, Khare SD, Krco CJ, Zhou P, Inoko H, Griffiths MM, Luthra HS, David CS.

Hum Immunol. 1996 Sep 15;50(1):54-60.

PMID:
8872175
28.

HLA-DQ8 transgenic mice lacking endogenous class II molecules respond to house dust allergens: identification of antigenic epitopes.

Neeno T, Krco CJ, Harders J, Baisch J, Cheng S, David CS.

J Immunol. 1996 May 1;156(9):3191-5.

PMID:
8617940
29.

Characterization of the antigenic structure of human type II collagen.

Krco CJ, Pawelski J, Harders J, McCormick D, Griffiths M, Luthra HS, David CS.

J Immunol. 1996 Apr 15;156(8):2761-8.

PMID:
8609394
30.
31.

H2-A polymorphism contributes to H2-Ebeta-mediated protection in collagen-induced arthritis.

Gonzalez-Gay MA, Zanelli E, Khare SD, Krco CJ, Griffiths MM, Luthra HS, David CS.

Immunogenetics. 1996;44(5):377-84.

PMID:
8781124
32.

Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis.

Khare SD, Krco CJ, Griffiths MM, Luthra HS, David CS.

J Immunol. 1995 Oct 1;155(7):3653-9.

PMID:
7561065
33.

Polymorphism of the MHC class II Eb gene determines the protection against collagen-induced arthritis.

Gonzalez-Gay MA, Zanelli E, Krco CJ, Nabozny GH, Hanson J, Griffiths MM, Luthra HS, David CS.

Immunogenetics. 1995;42(1):35-40.

PMID:
7797266
34.

Characterization of a novel 23-kilodalton protein of unactive progesterone receptor complexes.

Johnson JL, Beito TG, Krco CJ, Toft DO.

Mol Cell Biol. 1994 Mar;14(3):1956-63.

36.
37.

Genetic control of the immune response to Trichinella spiralis: recognition of muscle larval antigens.

Robinson M, Krco CJ, Beito TG, David CS.

Parasite Immunol. 1991 Jul;13(4):391-404.

PMID:
1923564
38.

Immunogenetic aspects of human thyroglobulin-reactive T cell lines and hybridomas.

Krco CJ, Gores A, David CS, Kong YM.

J Immunogenet. 1990 Dec;17(6):361-70.

PMID:
2096180
39.

The mouse antibody response to Trichinella spiralis defines a single, immunodominant epitope shared by multiple antigens.

Denkers EY, Wassom DL, Krco CJ, Hayes CE.

J Immunol. 1990 Apr 15;144(8):3152-9.

PMID:
1691229
40.

Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.

Pisani RJ, Krco CJ, Wold LE, McKean DJ.

Am J Clin Pathol. 1989 Oct;92(4):435-46.

PMID:
2552792
41.

Anti-mu treatment suppresses immunoglobulin light-chain gene expression and Peyer's patch development.

Woloschak GE, Krco CJ, Rodriguez M.

Mol Immunol. 1989 Apr;26(4):351-8.

PMID:
2497338
42.

The use of mouse class II MHC peptides to produce site-specific monoclonal antibodies.

Krco CJ, Beito TG, Little RG, Zeller J, McCormick DM, David CS.

Adv Exp Med Biol. 1989;251:181-5. Review. No abstract available.

PMID:
2692426
43.
45.

The impact of Jack Stimpfling's recombinants on immunogenetics.

Beito TG, Krco CJ, David CS.

Int Rev Immunol. 1988 Aug;3(4):323-31. Review. No abstract available.

PMID:
2854549
46.

Hormone-dependent processing of the avian progesterone receptor.

Sullivan WP, Smith DF, Beito TG, Krco CJ, Toft DO.

J Cell Biochem. 1988 Feb;36(2):103-19.

PMID:
3356750
48.

Genetic analysis of the H-2D region using a new intra-D-region recombinant mouse strain.

Duran LW, Zeller JC, Lundy JK, Chang-Miller A, Krco CJ, David CS, Pease LR.

J Immunol. 1987 Oct 15;139(8):2818-24.

PMID:
3309060
49.
50.

Characterization of immunologic and neuropathologic abnormalities in wasted mice.

Woloschak GE, Rodriguez M, Krco CJ.

J Immunol. 1987 Apr 15;138(8):2493-9.

PMID:
3494070

Supplemental Content

Support Center